mAbxience has selected the Genedata Bioprocess enterprise platform to structure and harmonize bioprocess development data across its operations. The company operates as a contract development and manufacturing organization (CDMO) focused on biosimilars and is majority-owned by the Fresenius Kabi group.
Andelyn Biosciences has announced the launch of The Andelyn Foundation, a nonprofit organization created to support families living with rare and ultra-rare diseases through awareness initiatives, fundraising activities, and community engagement. The company operates as a CDMO providing cell and
Samsung Biologics has entered a collaboration agreement with Eli Lilly and Company to establish a Lilly Gateway Labs (LGL) site in Korea. The facility will support early-stage and emerging biotechnology companies as they advance scientific research toward development and manufacturing.
Kenox Pharmaceuticals Inc. has expanded its analytical testing capabilities for orally inhaled and nasal drug products (OINDPs) by introducing Laser Diffraction and SprayVIEW systems for aerosol characterization. The upgrade enables testing of droplet size distribution (DSD), spray pattern (SP), and
Kenox Pharmaceuticals Inc. has announced that it is now clinical manufacturing ready and has expanded its GMP analytical testing capabilities for orally inhaled and nasal drug products (OINDPs). The company said the upgrades will support innovators developing nasal and inhaled
AsymBio, a subsidiary of Asymchem Group, has commenced operations at its Fengxian commercial manufacturing site in Shanghai. The launch completes the company’s Shanghai-based “Golden Triangle” network, which also includes the Zhangjiang Science & Technology Center and the Jinshan manufacturing site.
SimAbs has raised €5 million in a Series A funding round to expand its continuous manufacturing platform for antibodies and biosimilars. The investment brings together both existing and new strategic investors supporting the company’s biologics manufacturing approach. The company said
Neuland Laboratories Ltd. plans to open a commercial-scale peptide manufacturing facility in summer 2026 at its 17-acre Bonthapally campus in Hyderabad, India. The expansion aims to increase manufacturing capacity for complex peptides, including those used in GLP-1 therapies, amid rising
Lonza and Genetix Biotherapeutics Inc. have extended their long-term commercial manufacturing agreement to support demand for ZYNTEGLO™, a gene therapy approved in the United States for pediatric and adult patients with transfusion-dependent beta-thalassemia. Under the renewed agreement, Lonza will expand
Naobios, a contract development and manufacturing organization (CDMO) specializing in bioprocess development and GMP production of virus-based products, has partnered with SGS to manufacture a Respiratory Syncytial Virus (RSV) human viral challenge agent for Controlled Human Infection Model (CHIM) studies.
